Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial.

Authors:

Seyed Ehsan Mohammadianinejad Vahid Abbasi Seyed Aidin Sajedi Nastaran Majdinasab Fahimeh Abdollahi Reza Hajmanouchehri Asal Faraji

Clin Neuropharmacol 2011 Jul-Aug;34(4):174-7

Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Background: Topiramate is an antiepileptic drug that has been approved for migraine prophylaxis. Despite appropriate efficacy for migraine prophylaxis, some patients cannot tolerate its adverse effects. The aim of this study was to compare the efficacy of zonisamide, another antiepileptic drug, with topiramate in decreasing the frequency and severity of migraine attacks to determine whether it could be used as an alternative for noncompliant patients to topiramate.

Methods: Eighty patients, recruited from referred migraineurs to our neurology clinic, who met the diagnosis and inclusion criteria were allocated randomly to group A (50-mg/d zonisamide, gradually titrated up to 200 mg/d) and group B (25-mg/d topiramate, gradually titrated up to 100 mg/d). Each patient was followed for 12 weeks and was assessed at entrance, in the fourth week and twelfth week for frequency of attacks, headache severity, need for acute medication, migraine disability assessment score, and adverse effects. A P < 0.05 was considered as the level of significant difference in all tests.

Results: Both drugs caused a significant decrease in frequency, severity, need for acute medication in migraine attacks, and migraine disability assessment score (P < 0.05). Except headache severity that was reduced significantly better by zonisamide (P < 0.008), there were no significant difference between the 2 groups in other items. Except for 2 cases of intolerable paresthesia, both drugs were tolerated well during the study.

Conclusion: Our results indicated that zonisamide is as effective as topiramate in migraine prophylaxis and can be considered as an alternative treatment when topiramate is not tolerated well.

Download full-text PDF	Source
http://dx.doi.org/10.1097/WNF.0b013e318225140c	DOI Listing

December 2011

Publication Analysis

Altmetric Statistics

Similar Publications

Age-Dependent Differences in the Rate and Symptoms of TIA Mimics in Patients Presenting With a Suspected TIA to a Neurological Emergency Room.

Authors:

Franziska Maria Ippen Fabian Walter Christian Hametner Christoph Gumbinger Simon Nagel Jan C Purrucker Sibu Mundiyanapurath

Front Neurol 2021 15;12:644223. Epub 2021 Feb 15.

Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.

Transient ischemic attack (TIA) needs further diagnostic evaluation to prevent future ischemic stroke. However, prophylaxis can be harmful in elderly if the diagnosis is wrong. We aimed at characterizing differences in TIA mimics in younger and older patients to enhance diagnostic accuracy in elderly patients. Read More

View Article and Full-Text PDF

February 2021

Similar Publications

Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial.

Authors:

Richard B Lipton Sagar Munjal David W Dodick Stewart J Tepper Daniel Serrano Charlie Iaconangelo

J Pain Res 2021 25;14:549-560. Epub 2021 Feb 25.

Biostatistics Department, Pharmerit Inc., Bethesda, MD, USA.

Background: Nonsteroidal anti-inflammatory drugs are widely used for migraine, but gastrointestinal tolerability limits use. We previously reported results from the first treatment period of this 2-period, randomized, controlled study comparing DFN-15-an oral, ready-made liquid solution of a selective cyclo-oxygenase-2 inhibitor celecoxib-with placebo for the acute treatment of a moderate-severe migraine attack. Herein, we report the effects of treatment for the second treatment period. Read More

View Article and Full-Text PDF

February 2021

Similar Publications

Topiramate (Topamax) for Migraine Prophylaxis.

Authors:

Bing Li Paniz Johari Carolina Camacho Ruiz

Acad Emerg Med 2021 Mar 2. Epub 2021 Mar 2.

Department of Emergency Medicine, Kings County Hospital Center, Brooklyn, New York, USA.

The global prevalence of migraine headaches is estimated to be about 15%, consisting mostly of young and middle-aged adults. Migraine headaches not only cause a burden of pain and suffering, but also result in significant loss of productivity. For example, in the European Union migraines are estimated to cost nearly 50 billion Euros in lost productivity in terms of aggregate direct and indirect costs to society annually. Read More

View Article and Full-Text PDF

March 2021

Similar Publications

Evaluating rimegepant for the treatment of migraine.

Authors:

Tessa de Vries Linda Al-Hassany Antoinette Maassenvandenbrink

Expert Opin Pharmacother 2021 Mar 1. Epub 2021 Mar 1.

Erasmus MC, Department of Internal Medicine, Division of Pharmacology and Vascular Medicine, Rotterdam, 3000 CA Netherlands.

Introduction: Calcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide that plays an essential role in the pathophysiology of migraine, a highly disabling neurovascular disorder characterized by severe headache attacks. Rimegepant is a small-molecule CGRP receptor antagonist that is approved by the FDA for the acute treatment of migraine and currently under investigation for migraine prophylaxis.

Areas Covered: The authors summarize the available data on the safety and tolerability of rimegepant and provide our insights on its use for acute migraine treatment. Read More

View Article and Full-Text PDF

March 2021

Similar Publications